Skip to content

FDA Category 2 · restricted from compounding

This compound is on the FDA’s interim Section 503A Category 2 bulks list and cannot be legally compounded by US pharmacies. An HHS announcement in February 2026 signaled intent to restore several peptides to Category 1, but no Federal Register action has been published. Check the FDA PCAC schedule for updates.

Read the full regulatory context
PreclinicalTissue RepairOralDailyPartial data

BPC-157 + KPV (Capsules)

Combination oral capsule stacking BPC-157 and KPV for gut mucosal healing and anti-inflammatory effects.

§ 01   Overview

Overview

Combination oral capsule stacking BPC-157 and KPV for gut mucosal healing and anti-inflammatory effects.

Component data is preclinical. The specific combo has no controlled trials.

§ 02   Mechanism

Mechanism of action

BPC-157 promotes mucosal repair and angiogenesis while KPV suppresses NF-κB-driven inflammation. The combination targets both structural repair and inflammatory drivers in IBD-like conditions.

  • 01Targeted gut repair + anti-inflammatory
  • 02Convenient oral delivery for GI indications

§ 03   Dosing

Dosing protocol

Standard Protocol

Dose Range
500 mcg 1–2x daily
Route
Oral
Frequency
Daily
Cycle
4–8 weeks

§ 04   Evidence

Evidence & research

Preclinical

Component data is preclinical. The specific combo has no controlled trials.

FDA Status

Not FDA-approved. BPC-157 on FDA Negative List.

§ 05   Stacks

Common stacks

§ 07   Sourcing

Sourcing & supply

Regulatory status

Restricted from compounding

Placed on the FDA's 503A Category 2 list and cannot be lawfully compounded in the US. No brand pharmacy alternative exists. US buyers encounter only research-use-only (RUO) channels, which the FDA's Intended Use Doctrine treats as unapproved drug sales.

No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.

Browse full supplier directory

§ 09   Safety

Safety & side effects

Side effects

  • 01Generally well tolerated

Contraindications

None specified.

§ 10   Questions

BPC-157 + KPV (Capsules) FAQ

What is BPC-157 + KPV (Capsules)?
Combination oral capsule stacking BPC-157 and KPV for gut mucosal healing and anti-inflammatory effects. BPC-157 promotes mucosal repair and angiogenesis while KPV suppresses NF-κB-driven inflammation. The combination targets both structural repair and inflammatory drivers in IBD-like conditions.
What is BPC-157 + KPV (Capsules) used for?
Reported uses include targeted gut repair + anti-inflammatory and convenient oral delivery for gi indications. Evidence strength is rated Preclinical — see the evidence section for detail.
How is BPC-157 + KPV (Capsules) dosed?
Commonly referenced dosing is 500 mcg 1–2x daily, administered Oral. This is educational reference only; consult a licensed clinician before use.
What are the side effects of BPC-157 + KPV (Capsules)?
Commonly reported side effects include generally well tolerated. This list is not exhaustive.
Is BPC-157 + KPV (Capsules) legal?
Placed on the FDA's 503A Category 2 list and cannot be lawfully compounded in the US. No brand pharmacy alternative exists. US buyers encounter only research-use-only (RUO) channels, which the FDA's Intended Use Doctrine treats as unapproved drug sales. FDA status: Not FDA-approved. BPC-157 on FDA Negative List..

This site is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide or supplement.